Browse by Disease Classification

This page shows data for Gastrointestinal Disease Classification.
Total Entries Retrieved: 17
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10138 RotaTeq (RV5) Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved Merck & Co. Inc. NA USA 6 months - 8 months 3 doses at age of 2 months, 4 months, and 6 months Oral NA 5 human-bovine reassortant rotaviruses (G1, G2, G3 G4, P[8]) NA US FDA NA NA NA NA NA https://www.cdc.gov/vaccines/vpd/rotavirus/index.html https://www.fda.gov/media/75718/download
10139 Rotarix (RV1) Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved GlaxoSmithKline 2006 UK 6 months - 8 months 2 doses at ages 2 months and 4 months Oral NA Human rotavirus strain (G1P[8]) NA US FDA, EMA NA NA NA NA NA https://www.cdc.gov/vaccines/vpd/rotavirus/index.html https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
10140 Rotavac Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved Bharat Biotech International Limited 2013 India 6 months - 8 months 3 doses 4 weeks apart Oral NA Rotavirus 116E strain NA US FDA, Government of India NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://www.fda.gov/vaccines-blood-biologics/vaccines/rotavirus-vaccine-live-oral
10141 RotaSiil Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved Serum Institute of India 2017 India 6 months - 8 months 3 doses 4 weeks apart Oral NA Human-bovine reassortant rotaviruses (G1, G2, G3, G4, G9) NA National Institute of Health, Government of India NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
10235 VXA G1.1 NN Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 1 Vaxart NA USA NA NA Intranasal NA HuNoV GII.4 NA NA NA NA NA NA NA https://www.mdpi.com/2076-393X/9/7/732/htm NA
10236 Monovalent GI.1 VLPs Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 1 Baylor College of Medicine, University of Maryland School of Medicine NA USA NA NA Intranasal MPL HuNoV GI.1 NA NA NA NA NA NA NA https://www.mdpi.com/2076-393X/9/7/732/htm NA
10237 Transgenic plant-based norovirus vaccine Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 1 Arizona State University NA USA NA NA Intranasal Gardiquimod, None when delivered with GelVac Norwalk virus (GI.1) VLP Tobacco mosaic virus derived transient expression system using leaves of Nicotiana benthamiana NA NA NA NA NA NA https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf NA
10310 HIL-214 (Hillivax) Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 2 Takeda Pharmaceutical Company Limited 2012 USA 18 - 49 years 2 doses 28 days apart Intramuscular MPL, aluminium hydroxide GI.1 Norwalk VLP and GII.4 cVLP NA NA Frazier Healthcare Partners NA NA NA NCT01609257 https://clinicaltrials.gov/ct2/show/NCT01609257 NA
10311 Norovirus GI.1/GII.4 Bivalent VLP vaccine Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 2 Baylor College of Medicine 2014 USA 18 - 49 years NA Intramuscular MPL, Alum GI.1 and GII.4 consensus VLP Baculovirus expressed noroviruses VLPs NA NA NA NA NA NCT02142504 https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf https://clinicaltrials.gov/ct2/show/NCT02142504
10312 RV3-BB Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Phase 2 PT Biofarma NA Indonesia 0 - 5 days 3 doses regimen child schedule (0 to 5 days, 8 weeks, and 14 weeks of age or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age) Oral NA Three VP8 subunit proteins expressing P[4], P[6] and P[8] serotypes NA NA NA NA NA NA NA https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf NA
10377 Lamb rotavirus Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Phase 4 Lanzhou Biologicals 2000 China 6 months - 35 months NA Oral NA Single strain of rotavirus found in lamb (G10P) NA NA NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
10378 ROTAVIN-M1 Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Phase 4 Polyvac, Center for Research and Production of Vaccines NA Vietnam 6 months - 8 months NA Oral NA Human rotavirus strain (G1P) NA NA NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
10380 Trivalent combination vaccine Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Preclinical University of Tampere 2013 Finland NA NA Intramuscular, Intranasal NA GII-4, GI-3 VLP, rVP6 Baculovirus expressed noroviruses VLPs NA NA NA NA 23922988 NA https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724941/
10419 GII.4 P particles Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Preclinical Cincinnati Children’s Hospital Medical Center NA USA NA NA Intranasal NA P particles derived from HuNoV VP1 NA NA Southern Medical University, Virginia Polytechnic Institute and State University NA NA NA NA https://www.mdpi.com/2076-393X/9/7/732/htm https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851174/
10420 Plant-expressed GII.4 VLPs Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Preclinical Arizona State University NA USA NA NA Intranasal NA HuNoV GII.4 VLP NA NA NA NA NA NA NA https://www.mdpi.com/2076-393X/9/7/732/htm https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054422/
10421 GII.4 VLPs combined with EV71 VLPs Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Preclinical Institut Pasteur of Shanghai NA China NA NA Intramuscular NA HuNoV GII.4 and enterovirus 71 VLPs NA NA NA NA NA NA NA https://www.mdpi.com/2076-393X/9/7/732/htm NA
10422 Norovirus P particle and combination vaccines Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Subunit vaccine Preclinical Cincinnati Children’s Hospital Medical Center NA USA NA NA Intranasal Chitosan, MPL and TNC buffer P domains representing different GI and GII strains Baculovirus vector in E.coli or yeast system NA NA NA NA NA NA https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf NA